Posted on April 3, 20254/3/25
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
Posted on March 12, 20253/12/25
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
Posted on December 10, 202412/10/24
Association Between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes
Posted on December 9, 202412/9/24
Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia
Posted on November 26, 202411/26/24
The Importance of Quality-of-Life Metrics in mCRPC
Posted on November 6, 202411/6/24
Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways
Posted on November 4, 202411/4/24
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Posted on September 27, 20249/27/24
Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024
Posted on September 9, 20249/9/24
Tumor Types Drive Oncology Product Launch Strategies
Posted on June 5, 20246/5/24